CIITA and MHC II Transcription

Peterlin, Boris Matija

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Institute of Allergy and Infectious Diseases (NIAID)
• Type: Research Project (R01)
• Project #: 5R01AI050770-02
• Application #: 6765112
• Study Section: Immunobiology Study Section (IMB)
• Program Officer: Esch, Thomas R
• Project Start: 2003-07-01
• Project End: 2007-12-31
• Budget Start: 2004-01-01
• Budget End: 2004-12-31
• Support Year: 2
• Fiscal Year: 2004
• Total Cost: $303,000

Institution

• Name: University of California San Francisco
• Department: Internal Medicine/Medicine
• Type: Schools of Medicine
• DUNS #: 094878337
• City: San Francisco
• State: CA
• Country: United States
• Zip Code: 94143

Publications

Jabrane-Ferrat, N; Campbell, M J; Esserman, L J et al. (2006) Challenge with mammary tumor cells expressing MHC class II and CD80 prevents the development of spontaneously arising tumors in MMTV-neu transgenic mice. Cancer Gene Ther 13:1002-10

Drozina, Gorazd; Kohoutek, Jiri; Nishiya, Tadashi et al. (2006) Sequential modifications in class II transactivator isoform 1 induced by lipopolysaccharide stimulate major histocompatibility complex class II transcription in macrophages. J Biol Chem 281:39963-70

Peterlin, B Matija; Price, David H (2006) Controlling the elongation phase of transcription with P-TEFb. Mol Cell 23:297-305

Kanazawa, Satoshi; Ota, Shusuke; Sekine, Chiyoko et al. (2006) Aberrant MHC class II expression in mouse joints leads to arthritis with extraarticular manifestations similar to rheumatoid arthritis. Proc Natl Acad Sci U S A 103:14465-70